Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Companion Spine completed the acquisition of Paradigm Spine and its implants including Coflex® and CoFix® from Xtant Medical (NYSE:XTNT) on December 1, 2025. Paradigm Spine will retain its name and Wurmlingen, Germany office while joining Companion Spine's global portfolio.
Leadership roles were announced: Anthony G. Viscogliosi as Executive Chairman & CEO, Enrico Sangiorgio as EVP International and GM OUS, and William Pfost continuing as Chief Sales Officer focused on the U.S. The combined company now markets a broad set of posterior dynamic and motion-preserving implants, including multiple U.S. FDA PMA products.
Xtant Medical (NYSE: XTNT) completed the sale of certain non-core Coflex spinal implant assets and all OUS entities of Paradigm Spine to Companion Spine on Dec 1, 2025. The purchase price was approximately $19.2 million, consisting of $11.0 million cash and $8.2 million in short-term seller financing via an unsecured promissory note that is subject to purchase price adjustments and matures on Jan 15, 2026. Xtant intends to use net proceeds to reduce long-term debt and add liquidity, and said operating contributions of the sold assets are included through the Dec 1, 2025 sale date.
Xtant Medical (NYSE:XTNT) reported Q3 2025 revenue of $33.3M, up 19% YoY, with gross margin 66.1% versus 58.4% a year earlier. The company delivered net income $1.3M and adjusted EBITDA $4.5M, and generated $4.6M cash from operations. Cash and equivalents were $10.6M at 9/30/2025. Xtant reiterated full‑year 2025 revenue guidance of $131M–$135M (approx. 11%–15% growth over 2024).
Recent items: pending sale of certain hardware assets and all OUS businesses to Companion Spine expected to close by year‑end, and launch of CollagenX bovine collagen particulate for surgical wound closure. Webcast scheduled 11/11/2025 at 8:30 AM ET.
Xtant Medical (NYSE American: XTNT) announced the commercial launch of CollagenX™ on November 5, 2025. CollagenX is a bovine collagen particulate for surgical wound closure intended to promote healing, reduce dehiscence, and help mitigate concerns related to surgical site infections. The launch expands Xtant's biologics portfolio to address wound closure across spine, orthopedic, wound care, and other surgical disciplines. Management highlighted Xtant's vertical integration as a capability to deliver consistent quality for surgeons and patients.
Xtant Medical (NYSE American: XTNT) will release its third-quarter 2025 financial results for the period ended September 30, 2025 before market open on Tuesday, November 11, 2025. Sean Browne, President and CEO, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET the same day.
Conference dial-in details: 888-506-0062 (U.S.), international 973-528-0011, passcode 579614. A live webcast will be available at https://www.webcaster5.com/Webcast/Page/3039/52972, and a replay will be posted under Investor Info at https://xtantmedical.com/.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO Sean Browne and CFO Scott Neils will represent the company at the conference, which takes place September 8-10, 2025, in New York and virtually. The company's presentation will be available on-demand starting September 5 at 7:00 A.M. ET. Management will also conduct virtual one-on-one meetings with investors on September 8th.
Xtant Medical (NYSE American: XTNT) reported strong Q2 2025 financial results with revenue growing 18% to $35.4 million. The company achieved significant improvements, including a gross margin of 68.6% and net income of $3.6 million, compared to a net loss in the prior year.
Key developments include the planned sale of non-core assets to Companion Spine for $19.2 million and the launch of two new products: OsteoFactor Pro™ and Trivium™. The company has raised its FY25 revenue guidance to $131-135 million, projecting 11-15% growth. Operating performance showed marked improvement with Adjusted EBITDA of $6.9 million and positive operating cash flow of $1.2 million.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has announced its participation in the upcoming CG 45th Annual Growth Conference.
CEO Sean Browne and CFO Scott Neils will represent the company at the event, which is scheduled for August 12, 2025, at 3:30 PM ET in Boston, MA. The format will include both one-on-one meetings and a presentation. Interested parties can access the webcast through the provided link.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before market open.
The company will host a conference call at 8:30 AM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call through domestic (877-545-0523) and international (973-528-0016) dial-in numbers using passcode 482755. A webcast will be available, with a replay accessible on the company's website after the live call.
Companion Spine LLC has announced a definitive agreement to acquire Paradigm Spine GmbH and its spine implant portfolio from Xtant Medical Holdings (NYSE:XTNT). The acquisition includes the Coflex® and CoFix® spine implants, which have been used to treat over 390,000 patients globally.
The strategic acquisition positions Companion Spine as the world's largest provider of minimally invasive posterior dynamic spine stabilization solutions. The combined portfolio will offer comprehensive treatment options for lumbar spinal stenosis (LSS) and degenerative disc disease (DDD), with products distributed in more than 60 countries.
The transaction is expected to close in Q3 2025, subject to closing conditions. For Xtant Medical, the sale will allow focus on core business while reducing debt and improving their balance sheet.